| Identification | Back Directory | [Name]
MYCMI-6 | [CAS]
681282-09-7 | [Synonyms]
MYCMI-6
NSC354961
MYCMI-6(NSC 354961)
2,6-Pyridinediamine, 3-[2-(9-amino-7-ethoxy-3-acridinyl)diazenyl]- | [Molecular Formula]
C20H19N7O | [MDL Number]
MFCD32701920 | [MOL File]
681282-09-7.mol | [Molecular Weight]
373.41 |
| Chemical Properties | Back Directory | [Boiling point ]
699.5±55.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [form ]
Solid | [pka]
7.53±0.10(Predicted) | [color ]
Brown to reddish brown |
| Hazard Information | Back Directory | [Uses]
MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a Kd of 1.6?μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC50<0.5?μM). MYCMI-6 is not cytotoxic to normal human cells. MYCMI-6 induces apoptosis[1]. | [in vivo]
MYCMI-6 (20 mg/kg; i.p.; daily for 1-2 weeks) induces massive apoptosis and reduces tumor cell proliferation, tumor microvasculature density and MYC:MAX interaction in a MYC-dependent xenograft tumor model[1]. | Animal Model: | 6-8 weeks old athymic nude mice (bearing MYCN-amplified SK-N-DZ neuroblastoma cells)[1] | | Dosage: | 20?mg/kg body weight | | Administration: | I.p.; daily for 1-2 weeks | | Result: | A dramatic increase in the extension of apoptotic areas in the tumors and a significant increase in non-proliferative areas as determined by Ki67 staining in tumors.
|
| [References]
[1] Castell A, et al. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation. Sci Rep. 2018 Jul 3;8(1):10064. DOI:10.1038/s41598-018-28107-4 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|